Evidence map›Paper›PMID 29959821›Full record

ArticleCancer science2018

Resveratrol ameliorates Lewis lung carcinoma-bearing mice development, decreases granulocytic myeloid-derived suppressor cell accumulation and impairs its suppressive ability.

Yilin Zhao, Qi Shao, Haitao Zhu, Haiyuan Xu, Wei Long, Bin Yu, Lining Zhou, Huaxi Xu, Yan Wu, Zhaoliang Su

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Yilin ZhaoThe Central Laboratory, The Fourth Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Qi ShaoThe Central Laboratory, The Fourth Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Haitao ZhuThe Central Laboratory, The Fourth Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Haiyuan XuDepartment of Medical Oncology, Kunshan First People's Hospital Affiliated to Jiangsu University, Kunshan, China.
Wei LongThe Central Laboratory, Changzhou Woman and Children Health Hospital Affiliated to Nanjing Medical University, Changzhou, China.
Bin YuThe Central Laboratory, Changzhou Woman and Children Health Hospital Affiliated to Nanjing Medical University, Changzhou, China.
Lining ZhouDepartment of Immunology, Jiangsu University, Zhenjiang, China.
Huaxi XuThe Central Laboratory, The Fourth Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Yan WuThe Central Laboratory, The Fourth Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Zhaoliang SuThe Central Laboratory, The Fourth Affiliated Hospital of Jiangsu University, Zhenjiang, China.ORCID http://orcid.org/0000-0002-5998-5575
Jiangsu University · CNChangzhou No.2 People's Hospital · CN

Funding

Key University Science Research Project of Jiangsu Province 16KJA320005Maternal and Child Project in Jiangsu Province F201511Medical Development Foundation of Jiangsu University JLY20160051Six Talent Peaks Project in Jiangsu Province 2015-WSN-005Social Development Foundation of Jiangsu Province BE2016716
6 · The paper itself

Abstract

Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of immature myeloid cells which consist of 2 subsets: granulocytic MDSC (G-MDSC) and monocytic MDSC (M-MDSC). MDSC expand in tumor-bearing hosts and contribute to immunotherapeutic resistance by remarkably blocking effector T-cell activation via different mechanisms. Resveratrol (RSV) is a polyphenol and it has been widely used for its various health benefits. However, the underlying mechanism of its anti-tumor properties remains unclear. In this study, a transplantable mouse model was used to investigate the effects of RSV on MDSC. The results showed that RSV ameliorated tumor development by decreasing G-MDSC accumulation, impairing its suppressive ability on CD8

Indexed as

AnimalsApoptosisCarcinoma, Lewis LungCD8-Positive T-LymphocytesCell Line, TumorHMGB1 ProteinInterferon-gammaMaleMiceMice, Inbred C57BLMyeloid-Derived Suppressor CellsResveratrolStilbenesHMGB1 ProteinHMGB1 protein, mouseInterferon-gammaResveratrolStilbenesHMGB1macrophagemyeloid-derived suppressor cellsresveratroltumor immunotherapy

Identifiers

PMID29959821
PMCPMC6125446
OpenAlexW2811249451

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.